Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary NeuroMetrix Reports Agreement with GSK Healthcare on 2019 Quell Joint Development Program and Modification to Strategic Collaboration
WALTHAM, Mass. , Dec. 11, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq: NURO) today reported momentum in its strategic collaboration with GSK Consumer Healthcare . Under terms of the collaboration entered into in the first quarter of 2018, the parties committed to co-fund future development
View HTML
Toggle Summary NeuroMetrix to Present at the LD Micro 11th Annual Main Event on December 5, 2018
WALTHAM, Mass. , Nov. 28, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (NASDAQ:NURO) today announced that Shai N. Gozani M.D., Ph.D., President and CEO of NeuroMetrix, is scheduled to speak at the upcoming LD Micro Annual Main Event at the Luxe Sunset Bel Air Hotel in Los Angeles, CA. Dr.
View HTML
Toggle Summary NeuroMetrix Announces Issuance of New U.S. Patent for Quell Wearable Technology
WALTHAM, Mass. , Nov. 20, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq:NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,130,810 titled “Transcutaneous electrical nerve stimulation with user gesture detector and electrode-skin contact detector,
View HTML
Toggle Summary NeuroMetrix Announces DPNCheck Collaboration Agreement with Fukuda Denshi for Japan Market
WALTHAM, Mass. , Nov. 15, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), announced today that it had executed a distribution agreement with Fukuda Denshi Co. Ltd. for DPNCheck ® , the Company’s  rapid, point-of-care test for diabetic peripheral neuropathy (DPN).
View HTML
Toggle Summary NeuroMetrix Announces Issuance of New U.S. Patent for Quell Wearable Technology
WALTHAM, Mass. , Oct. 31, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq:NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,112,040 titled “Transcutaneous electrical nerve stimulation using novel unbalanced biphasic waveform and novel electrode
View HTML
Toggle Summary NeuroMetrix Reports DPNCheck to be Featured at Upcoming 33rd Japan Society of Diabetic Complications Annual Meeting in Tokyo
WALTHAM, Mass. , Oct. 18, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), reported that DPNCheck ® , its rapid, point-of-care test for diabetic peripheral neuropathy (DPN), will be featured in several scientific sessions at the 33 rd Japan Society of Diabetic Complications Meeting in
View HTML
Toggle Summary NeuroMetrix Reports Q3 2018 Financial Results
$3.8M GSK Milestone; Improved Operating Performance WALTHAM, Mass. , Oct. 17, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), today reported financial and business highlights for the quarter ended September 30, 2018 . The Company develops and markets novel therapies for chronic health
View HTML
Toggle Summary NeuroMetrix, Inc. Announces Date for 2018 Third Quarter Financial Results Conference Call
WALTHAM, Mass. , Oct. 10, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (NASDAQ:NURO) announced today that it plans to issue its 2018 third quarter financial results before the opening of the market on Wednesday, October 17, 2018. The Company will host a conference call at 8:00 a.m., Eastern
View HTML
Toggle Summary NeuroMetrix Reports Publication of New Clinical Study on Quell Wearable Pain Relief Technology
WALTHAM, Mass. , Oct. 02, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported publication of a clinical study of Quell ® wearable pain relief in the Journal of Pain and Relief.  The paper is titled “Real-World Evidence for the Widespread Effects of Fixed-Site High Frequency
View HTML
Toggle Summary NeuroMetrix To Present Quell 2.0 at DTxDM East: The Digital Therapeutics and Digital Medicine Event in Boston
WALTHAM, Mass. , Sept. 25, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today announced that it will showcase its latest product innovation, Quell ® 2.0 Wearable Pain Relief Technology™, during a workshop at DTxDM East, and will discuss using real world, patient generated data to
View HTML